| Year |
Citation |
Score |
| 2024 |
Li X, Mu P. Restoring our ubiquitination machinery to overcome resistance in cancer therapy. Oncoscience. 11: 43-44. PMID 38711948 DOI: 10.18632/oncoscience.600 |
0.451 |
|
| 2024 |
Xu Y, Yang Y, Wang Z, Sjostrom M, Jiang Y, Tang Y, Cheng S, Deng S, Wang C, Gonzalez J, Johnson NA, Li X, Li X, Metang LA, Mukherji A, ... ... Mu P, et al. ZNF397 Deficiency Triggers TET2-driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer. Cancer Discovery. PMID 38591846 DOI: 10.1158/2159-8290.CD-23-0539 |
0.585 |
|
| 2023 |
Rodriguez Tirado C, Wang C, Li X, Deng S, Gonzalez J, Johnson NA, Xu Y, Metang LA, Sundar Rajan M, Yang Y, Yin Y, Hofstad M, Raj GV, Zhang S, Lemoff A, ... ... Mu P, et al. UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance. Oncogene. PMID 38030789 DOI: 10.1038/s41388-023-02890-5 |
0.426 |
|
| 2023 |
Xu Y, Wang Z, Sjöström M, Deng S, Wang C, Johnson NA, Gonzalez J, Li X, Metang LA, Tirado CR, Mukherji A, Wainwright G, Yu X, Yang Y, Barnes S, ... ... Mu P, et al. ZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent Cancers. Biorxiv : the Preprint Server For Biology. PMID 37961351 DOI: 10.1101/2023.10.24.563645 |
0.552 |
|
| 2023 |
Li X, Mu P. The Critical Interplay of CAF Plasticity and Resistance in Prostate Cancer. Cancer Research. PMID 37504898 DOI: 10.1158/0008-5472.CAN-23-2260 |
0.64 |
|
| 2023 |
Li X, Wang Y, Deng S, Zhu G, Wang C, Johnson NA, Zhang Z, Tirado CR, Xu Y, Metang LA, Gonzalez J, Mukherji A, Ye J, Yang Y, Peng W, ... ... Mu P, et al. Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer. Cancer Cell. PMID 37478850 DOI: 10.1016/j.ccell.2023.06.010 |
0.549 |
|
| 2022 |
Deng S, Wang C, Wang Y, Xu Y, Li X, Johnson NA, Mukherji A, Lo UG, Xu L, Gonzalez J, Metang LA, Ye J, Tirado CR, Rodarte K, Zhou Y, ... ... Mu P, et al. Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance. Nature Cancer. PMID 36065066 DOI: 10.1038/s43018-022-00431-9 |
0.478 |
|
| 2022 |
Lo UG, Chen YA, Cen J, Deng S, Luo J, Zhau H, Ho L, Lai CH, Mu P, Chung LWK, Hsieh JT. The driver role of JAK-STAT signalling in cancer stemness capabilities leading to new therapeutic strategies for therapy- and castration-resistant prostate cancer. Clinical and Translational Medicine. 12: e978. PMID 35908276 DOI: 10.1002/ctm2.978 |
0.572 |
|
| 2022 |
Chen L, Mu B, Li Y, Lu F, Mu P. DRR1 promotes neuroblastoma cell differentiation by regulating CREB expression. Pediatric Research. PMID 35854089 DOI: 10.1038/s41390-022-02192-8 |
0.301 |
|
| 2022 |
de Wet L, Williams A, Gillard M, Kregel S, Lamperis S, Gutgesell LC, Vellky JE, Brown R, Conger K, Paner GP, Wang H, Platz EA, De Marzo AM, Mu P, Coloff JL, et al. Correction to: SOX2 mediates metabolic reprogramming of prostate cancer cells. Oncogene. 41: 1234. PMID 35145235 DOI: 10.1038/s41388-022-02228-7 |
0.471 |
|
| 2022 |
de Wet L, Williams A, Gillard M, Kregel S, Lamperis S, Gutgesell LC, Vellky JE, Brown R, Conger K, Paner GP, Wang H, Platz EE, De Marzo AM, Mu P, Coloff JL, et al. SOX2 mediates metabolic reprogramming of prostate cancer cells. Oncogene. PMID 35067686 DOI: 10.1038/s41388-021-02157-x |
0.584 |
|
| 2020 |
Blatt EB, Kopplin N, Kumar S, Mu P, Conzen SD, Raj GV. Overcoming oncogene addiction in breast and prostate cancers: a comparative mechanistic overview. Endocrine-Related Cancer. PMID 33263560 DOI: 10.1530/ERC-20-0272 |
0.554 |
|
| 2020 |
Zhang Z, Karthaus WR, Lee YS, Gao VR, Wu C, Russo JW, Liu M, Mota JM, Abida W, Linton E, Lee E, Barnes SD, Chen HA, Mao N, Wongvipat J, ... ... Mu P, et al. Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. Cancer Cell. PMID 32679108 DOI: 10.1016/J.Ccell.2020.06.005 |
0.696 |
|
| 2020 |
Zhang Z, Zhou C, Li X, Barnes SD, Deng S, Hoover E, Chen CC, Lee YS, Zhang Y, Wang C, Metang LA, Wu C, Tirado CR, Johnson NA, Wongvipat J, ... ... Mu P, et al. Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation. Cancer Cell. PMID 32220301 DOI: 10.1016/J.Ccell.2020.03.001 |
0.631 |
|
| 2020 |
Lu F, Cui D, Mu B, Zhao L, Mu P. Downregulation of TMOD1 promotes cell motility and cell proliferation in cervical cancer cells. Oncology Letters. 19: 3339-3348. PMID 32218869 DOI: 10.3892/ol.2020.11410 |
0.33 |
|
| 2020 |
Lo U, Chen Y, Mu P, Lin H, Lai C, Hsieh J. Abstract 6028: Interferon induces lineage plasticity of castration-resistant prostate cancer Cancer Research. 80: 6028-6028. DOI: 10.1158/1538-7445.Am2020-6028 |
0.661 |
|
| 2019 |
Lin CJ, Yun EJ, Lo UG, Tai YL, Deng S, Hernandez E, Dang A, Chen YA, Saha D, Mu P, Lin H, Li TK, Shen TL, Lai CH, Hsieh JT. The paracrine induction of prostate cancer progression by caveolin-1. Cell Death & Disease. 10: 834. PMID 31685812 DOI: 10.1038/S41419-019-2066-3 |
0.621 |
|
| 2019 |
Zhang Z, Karthaus W, Mota JM, Mu P, Wu C, Abida W, Linton E, Lee YS, Lee E, Mao N, Adams E, Choi D, Rathkopf DE, Carver B, Gopalan A, et al. Abstract 111: Tumor microenvironment derived NRG1 promotes antiandrogen resistance in prostate cancer Cancer Research. 79: 111-111. DOI: 10.1158/1538-7445.Am2019-111 |
0.703 |
|
| 2017 |
Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, Wongvipat J, Ku SY, Gao D, Cao Z, Shah N, Adams EJ, Abida W, Watson PA, Prandi D, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science (New York, N.Y.). 355: 84-88. PMID 28059768 DOI: 10.1126/Science.Aah4307 |
0.676 |
|
| 2017 |
Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, Goodrich MM, Labbé DP, Gomez EC, Wang J, Long HW, Xu B, Brown M, Loda M, Sawyers CL, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science (New York, N.Y.). 355: 78-83. PMID 28059767 DOI: 10.1126/Science.Aah4199 |
0.682 |
|
| 2017 |
Mu P, Zhang Z, Benelli M, Karthaus W, Hoover E, Chen C, Wongvipat J, Ku S, Gao D, Cao Z, Shah N, Adams E, Abida W, Watson P, Prandi D, et al. Abstract 4165:SOX2promotes lineage plasticity and antiandrogen resistance inTP53andRB1deficient prostate cancer Cancer Research. 77: 4165-4165. DOI: 10.1158/1538-7445.Am2017-4165 |
0.633 |
|
| 2017 |
Ku S, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich Z, Goodrich M, Labbé DP, Gomez EC, Wang J, Long HW, Xu B, Brown M, Loda M, Sawyers CL, et al. Abstract 2170:Rb1suppresses prostate cancer metastasis and lineage plasticity underlying castration resistance Cancer Research. 77: 2170-2170. DOI: 10.1158/1538-7445.Am2017-2170 |
0.637 |
|
| 2015 |
Mu P, Deng S, Fan X. MicroRNAs in Prostate Cancer: Small RNAs with Big Roles Journal of Clinical & Cellular Immunology. 6: 1-9. DOI: 10.4172/2155-9899.1000315 |
0.506 |
|
| 2015 |
Mu P, Cao Z, Hoover E, Wongvipat J, Huang C, Karthaus W, Abida W, Stanchina ED, Sawyers C. Abstract LB-056: TP53 and RB1 alterations promote reprogramming and antiandrogen resistance in advanced prostate cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-056 |
0.698 |
|
| 2011 |
Huang P, Kishida S, Cao D, Murakami-Tonami Y, Mu P, Nakaguro M, Koide N, Takeuchi I, Onishi A, Kadomatsu K. The neuronal differentiation factor NeuroD1 downregulates the neuronal repellent factor Slit2 expression and promotes cell motility and tumor formation of neuroblastoma. Cancer Research. 71: 2938-48. PMID 21349947 DOI: 10.1158/0008-5472.CAN-10-3524 |
0.305 |
|
| 2009 |
Mu P, Nagahara S, Makita N, Tarumi Y, Kadomatsu K, Takei Y. Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer. International Journal of Cancer. 125: 2978-90. PMID 19422046 DOI: 10.1002/ijc.24382 |
0.408 |
|
| Show low-probability matches. |